New Taiho, Cullinan data heats up lung cancer drug battle

BiopharmadiveView source article

Part of story

Taiho and Cullinan's zipalertinib succeeds in phase 3 lung cancer trial

Taiho Oncology and Cullinan Therapeutics announced their next-generation EGFR inhibitor zipalertinib significantly improved progression-free survival in a registrational phase 3 trial for first-line treatment of advanced non-small cell lung cancer. The results position the drug as a competitor to multiple approved medicines in the EGFR-mutated lung cancer market.

Aug 13, 20264 sourcesClinical trials

Taiho and Cullinan's zipalertinib succeeds in phase 3 lung cancer trial

Other sources for this story

Fiercepharma

Fierce Pharma Asia—Legend’s first profit; Taiho, Cullinan’s EGFR win; WuXi AppTec’s reprieve

Biospace

Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition

Endpoints

New Taiho, Cullinan data heats up lung cancer drug battle

Part of story

Taiho and Cullinan's zipalertinib succeeds in phase 3 lung cancer trial

Other sources for this story

Fierce Pharma Asia—Legend’s first profit; Taiho, Cullinan’s EGFR win; WuXi AppTec’s reprieve

Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition

Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contest

New Taiho, Cullinan data heats up lung cancer drug battle

Part of story

Taiho and Cullinan's zipalertinib succeeds in phase 3 lung cancer trial

Other sources for this story

Fierce Pharma Asia—Legend’s first profit; Taiho, Cullinan’s EGFR win; WuXi AppTec’s reprieve

Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition

Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contest